We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prestige Consumer (PBH) to Post Q3 Earnings: Things to Know
Read MoreHide Full Article
Prestige Consumer Healthcare Inc. (PBH - Free Report) is slated to report third-quarter fiscal 2020 results on Feb 6. This healthcare product provider delivered a positive earnings surprise of 4.6% in the last reported quarter. Further, its earnings have outperformed the Zacks Consensus Estimate by nearly 3%, on average, in the trailing four quarters.
The Zacks Consensus Estimate for third-quarter earnings has been stable at 75 cents per share over the past 30 days. This suggests an increase of 2.7% from the year-ago period’s reported figure. However, the consensus mark for revenues stands at $241 million, indicating a dip of 0.4% from the figure reported in the year-ago period.
Prestige Consumer Healthcare Inc. Price and EPS Surprise
Prestige Consumer has been benefiting from its transformation efforts and a strong focus on the healthcare business. Also, the company’s invest-for-growth strategy has been yielding results. Further, the company’s focus on marketing initiatives and innovation bodes well. Apart from this, e-commerce strength has been a driver for Prestige Consumer. The company’s online sales grew considerably in the first half of fiscal 2020. Management, in its last earnings call, stated that it expects continued online sales growth for fiscal 2020, which bodes well for the third quarter.
Markedly, Prestige Consumer’s International OTC Healthcare segment has been performing well for quite some time, courtesy of increased consumption. The Zacks Consensus Estimate for third-quarter revenues of this segment stands at $25.1 million, suggesting growth from $24.6 million reported in the year-ago period.
However, the company’s North American OTC Healthcare segment has been seeing softness owing to retailer inventory reductions. The consensus mark for third-quarter revenues of this segment is pegged at $217 million, which is in line with revenues reported in the year-ago period. Apart from this, the company has been encountering foreign currency headwinds. In its last earnings call, management stated that it expects currency headwinds to weigh on the top line in fiscal 2020, which may have been a deterrent in the quarter under review as well.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Prestige Consumer this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Although Prestige Consumer carries a Zacks Rank #3, its Earnings ESP of 0.00% makes surprise prediction difficult.
Stocks With Favorable Combinations
Here are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat:
Crocs, Inc. (CROX - Free Report) presently has an Earnings ESP of +30.00% and a Zacks Rank #3.
Adidas (ADDYY - Free Report) currently has an Earnings ESP of +1.06% and a Zacks Rank #3.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.7% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Prestige Consumer (PBH) to Post Q3 Earnings: Things to Know
Prestige Consumer Healthcare Inc. (PBH - Free Report) is slated to report third-quarter fiscal 2020 results on Feb 6. This healthcare product provider delivered a positive earnings surprise of 4.6% in the last reported quarter. Further, its earnings have outperformed the Zacks Consensus Estimate by nearly 3%, on average, in the trailing four quarters.
The Zacks Consensus Estimate for third-quarter earnings has been stable at 75 cents per share over the past 30 days. This suggests an increase of 2.7% from the year-ago period’s reported figure. However, the consensus mark for revenues stands at $241 million, indicating a dip of 0.4% from the figure reported in the year-ago period.
Prestige Consumer Healthcare Inc. Price and EPS Surprise
Prestige Consumer Healthcare Inc. price-eps-surprise | Prestige Consumer Healthcare Inc. Quote
Key Factors to Note
Prestige Consumer has been benefiting from its transformation efforts and a strong focus on the healthcare business. Also, the company’s invest-for-growth strategy has been yielding results. Further, the company’s focus on marketing initiatives and innovation bodes well. Apart from this, e-commerce strength has been a driver for Prestige Consumer. The company’s online sales grew considerably in the first half of fiscal 2020. Management, in its last earnings call, stated that it expects continued online sales growth for fiscal 2020, which bodes well for the third quarter.
Markedly, Prestige Consumer’s International OTC Healthcare segment has been performing well for quite some time, courtesy of increased consumption. The Zacks Consensus Estimate for third-quarter revenues of this segment stands at $25.1 million, suggesting growth from $24.6 million reported in the year-ago period.
However, the company’s North American OTC Healthcare segment has been seeing softness owing to retailer inventory reductions. The consensus mark for third-quarter revenues of this segment is pegged at $217 million, which is in line with revenues reported in the year-ago period. Apart from this, the company has been encountering foreign currency headwinds. In its last earnings call, management stated that it expects currency headwinds to weigh on the top line in fiscal 2020, which may have been a deterrent in the quarter under review as well.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Prestige Consumer this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Although Prestige Consumer carries a Zacks Rank #3, its Earnings ESP of 0.00% makes surprise prediction difficult.
Stocks With Favorable Combinations
Here are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat:
The Gap, Inc. (GPS - Free Report) currently has an Earnings ESP of +5.43% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Crocs, Inc. (CROX - Free Report) presently has an Earnings ESP of +30.00% and a Zacks Rank #3.
Adidas (ADDYY - Free Report) currently has an Earnings ESP of +1.06% and a Zacks Rank #3.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.7% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>